

Andrew M Evens

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5698032/andrew-m-evens-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

261
papers

10,487
citations

51
h-index

97
g-index

277
ext. papers

12,134
ext. citations

4.8
avg. IF

5.73
L-index

#	Paper	IF	Citations
261	Survivorship transition care experiences and preparedness for survivorship among a diverse population of cancer survivors in New Jersey.. <i>European Journal of Cancer Care</i> , 2022 , e13553	2.4	1
260	Treatment Strategies for Advanced Classical Hodgkin Lymphoma in the Times of Dacarbazine Shortage.. <i>JCO Oncology Practice</i> , 2022 , OP2100890	2.3	1
259	Association of Treatment Intensity With Survival in Older Patients With Hodgkin Lymphoma. <i>JAMA Network Open</i> , 2021 , 4, e2128373	10.4	1
258	Oncogenic Integration of Nucleotide Metabolism Fatty Acid Synthase in Non-Hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2021 , 11, 725137	5.3	2
257	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1129-1138	2.2	7
256	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021 , 5, 2852-2862	7.8	5
255	Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy. <i>Journal of Geriatric Oncology</i> , 2021 , 12, 1233-1239	3.6	0
254	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , 2021 , 137, 374-386	2.2	19
253	Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. <i>Blood</i> , 2021 , 137, 1318-1326	2.2	25
252	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021 , 106, 1932-1942	6.6	8
251	SARS-CoV-2 nosocomial infection: Real-world results of environmental surface testing from a large tertiary cancer center. <i>Cancer</i> , 2021 , 127, 1926-1932	6.4	3
250	Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. <i>Blood Advances</i> , 2021 , 5, 3623-3632	7.8	1
249	A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas. <i>Leukemia and Lymphoma</i> , 2021 , 1-8	1.9	1
248	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2442-2447	1.9	0
247	A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. <i>Clinical Cancer Research</i> , 2020 , 26, 4468-4477	12.9	4
246	How I treat advanced Hodgkin lymphoma - a global view. <i>British Journal of Haematology</i> , 2020 , 190, 837-850	4.5	1
245	First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study. <i>British Journal of Haematology</i> , 2020 , 190, 222-235	4.5	4

244	A systematic review of therapeutic regimens for older patients with newly diagnosed Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1555-1564	1.9	0
243	Current Treatment Options for Older Patients with Hodgkin Lymphoma. <i>Current Treatment Options in Oncology</i> , 2020 , 21, 42	5.4	2
242	The Management of Older Patients with Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2020 , 297-315		0
241	Optimizing Decision Making in Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2020 , 265-273	0	1
240	Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma. <i>Leukemia</i> , 2020 , 34, 1291-1304	10.7	22
239	Lymphoma Occurring During Pregnancy: Current Diagnostic and Therapeutic Approaches. <i>Current Oncology Reports</i> , 2020 , 22, 113	6.3	0
238	Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma. <i>British Journal of Haematology</i> , 2020 , 188, 295-308	4.5	2
237	Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 104, 436-446	4	1
236	Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2019 , 37, 471-480	2.2	44
235	Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. <i>Blood</i> , 2019 , 133, 1762-1765	2.2	19
234	Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. <i>Blood</i> , 2019 , 134, 1238-1246	2.2	50
233	The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2019 , 10, 2030-2040	3.3	43
232	Longitudinal toxicity analysis with novel summary metrics of lenalidomide maintenance in follicular lymphoma in ECOG-ACRIN 2408.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6511-6511	2.2	
231	Management of older Hodgkin lymphoma patients. <i>Hematology American Society of Hematology Education Program</i> , 2019 , 2019, 233-242	3.1	3
230	Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models. <i>Scientific Reports</i> , 2019 , 9, 17161	4.9	12
229	Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. <i>British Journal of Haematology</i> , 2019 , 184, 524-535	4.5	16
228	Microfluidic assembly of hydrogel-based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release. <i>Journal of Controlled Release</i> , 2019 , 295, 21-30	11.7	31
227	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. <i>Leukemia and Lymphoma</i> , 2019 , 60, 940-946	1.9	2

226	Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. <i>Leukemia and Lymphoma</i> , 2019 , 60, 894-903	1.9	7
225	Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL. <i>Nature Communications</i> , 2018 , 9, 829	17.4	37
224	Does Q fever contribute to pathogenesis of non-Hodgkin lymphoma?. <i>Lancet Haematology</i> , 2018 , 5, e186-e187	14.6	
223	Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL. <i>Scientific Reports</i> , 2018 , 8, 744	4.9	24
222	Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. <i>British Journal of Haematology</i> , 2018 , 182, 212-221	4.5	7
221	University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. <i>British Journal of Haematology</i> , 2018 , 181, 264-267	4.5	2
220	Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. <i>Cancer</i> , 2018 , 124, 136-144	6.4	34
219	Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study. <i>Blood</i> , 2018 , 132, 1618-1618	2.2	7
218	Assessing the risk of cardiac toxicity after contemporary treatment for Hodgkin lymphoma: a systematic review. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1976-1980	1.9	2
217	Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3015-3022	2.2	57
216	Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. <i>Oncotarget</i> , 2018 , 9, 22693-22702	3.3	10
215	The Genetic Basis of Hepatosplenic T-cell Lymphoma. <i>Cancer Discovery</i> , 2017 , 7, 369-379	24.4	105
214	Toxicities, response and survival: Autologous stem cell transplantation for multiple myeloma over 25 years at a single center. <i>Cancer Treatment and Research Communications</i> , 2017 , 11, 1-5	2	
213	Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	22
212	Genetic and Functional Drivers of Diffuse Large BCell Lymphoma. <i>Cell</i> , 2017 , 171, 481-494.e15	56.2	499
211	C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. <i>Cancer</i> , 2017 , 123, 4411-4418	6.4	19
210	Periodontal disease and risk of non-Hodgkin lymphoma in the Health Professionals Follow-Up Study. <i>International Journal of Cancer</i> , 2017 , 140, 1020-1026	7.5	22
209	Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. <i>American Journal of Hematology</i> , 2017 , 92, 161-170	7.1	43

208	Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. <i>Blood Advances</i> , 2017 , 1, 2600-2609	7.8	43
207	Dynamic Analysis of Human Natural Killer Cell Response at Single-Cell Resolution in B-Cell Non-Hodgkin Lymphoma. <i>Frontiers in Immunology</i> , 2017 , 8, 1736	8.4	31
206	A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma. <i>PLoS ONE</i> , 2017 , 12, e0170521	3.7	12
205	Gray Zone Lymphoma: Current Diagnosis and Treatment Options. <i>Hematology/Oncology Clinics of North America</i> , 2016 , 30, 1251-1260	3.1	9
204	De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. <i>American Journal of Hematology</i> , 2016 , 91, 395-9	7.1	32
203	Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival. <i>American Journal of Hematology</i> , 2016 , 91, 560-5	7.1	22
202	Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. <i>Journal of Clinical Oncology</i> , 2016 , 34, 501-8	2.2	49
201	Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma. <i>Cancer Research</i> , 2016 , 76, 3319-31	10.1	28
200	The evolving role of response-adapted PET imaging in Hodgkin lymphoma. <i>Therapeutic Advances in Hematology</i> , 2016 , 7, 108-25	5.7	10
199	A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2016 , 22, 1059-66	12.9	52
198	Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7507-7507	2.2	5
197	PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. <i>Oncotarget</i> , 2016 , 7, 59976-59986	3.3	45
196	Managing Lymphoma During Pregnancy 2016 , 159-173		
195	Health-related quality of life (HRQL) in Hodgkin lymphoma (HL): A systematic review (SR).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 234-234	2.2	
194	Circulating microRNAs Predict the Initiation of NHL in a Novel In Vivo Model: Impact of Age and Sex Via a Systems Biology Approach. <i>Blood</i> , 2016 , 128, 4114-4114	2.2	
193	Health-related quality of life in Hodgkin lymphoma: a systematic review. <i>Health and Quality of Life Outcomes</i> , 2016 , 14, 114	3	29
192	How I manage patients with grey zone lymphoma. <i>British Journal of Haematology</i> , 2016 , 174, 345-50	4.5	16
191	A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. <i>British Journal of Haematology</i> , 2016 , 172, 535-44	4.5	56

190	Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. <i>Blood</i> , 2016 , 128, 2199-2205	2.2	135
189	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2020-7	2.2	184
188	Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1543-1551	4.7	34
187	Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 684-692.e3	2	11
186	Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). <i>Leukemia</i> , 2015 , 29, 886-94	10.7	65
185	Current therapeutic strategies and new treatment paradigms for follicular lymphoma. <i>Cancer Treatment and Research</i> , 2015 , 165, 197-226	3.5	9
184	Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 971-83	4.7	51
183	Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. <i>Clinical Cancer Research</i> , 2015 , 21, 113-22	12.9	101
182	Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. <i>Blood</i> , 2015 , 125, 2471-6	2.2	48
181	Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. <i>American Journal of Hematology</i> , 2015 , 90, 778-83	7.1	53
180	The Impact of Age and Sex in DLBCL: Systems Biology Analyses Identify Distinct Molecular Changes and Signaling Networks. <i>Cancer Informatics</i> , 2015 , 14, 141-8	2.4	15
179	Paraneoplastic pyoderma gangrenosum with posttransplant lymphoproliferative disorder. <i>Annals of Hematology</i> , 2015 , 94, 893-4	3	3
178	Proton irradiation impacts age-driven modulations of cancer progression influenced by immune system transcriptome modifications from splenic tissue. <i>Journal of Radiation Research</i> , 2015 , 56, 792-803 ^{2,4}		7
177	Patient-Derived Xenografts (PDX) of B Cell Lymphoma in NSG Mice: A Mouse Avatar for Developing Personalized Medicine. <i>Blood</i> , 2015 , 126, 5408-5408	2.2	4
176	The Management of Older Patients with Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2015 , 271-286 ○		
175	An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy. <i>Blood</i> , 2015 , 126, 2635-2635	2.2	
174	Periodontal Disease and Risk of Non Hodgkin Lymphoma (NHL) in the Health Professionals Follow-up Study (HPFS). <i>Blood</i> , 2015 , 126, 5024-5024	2.2	
173	A Comparative Oncology Analysis of Canine T-Cell Lymphoma (TCL): Immunohistochemical Study and Next Generation Sequencing for Protein Analysis and Genomic Target Discovery. <i>Blood</i> , 2015 , 126, 3883-3883	2.2	

172	Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. <i>British Journal of Haematology</i> , 2014 , 166, 514-20	4.5	17
171	F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014 , 165, 793-800	4.5	34
170	Multiple successful desensitizations to brentuximab vedotin: a case report and literature review. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 465-71	7.3	21
169	Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. <i>Blood</i> , 2014 , 123, 2895-7	2.2	43
168	The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. <i>Blood</i> , 2014 , 124, 3356-64	2.2	30
167	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood</i> , 2014 , 124, 2354-61	2.2	306
166	The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. <i>Hematology American Society of Hematology Education Program</i> , 2014 , 2014, 135-43	3.1	8
165	The impact of race, age, and sex in follicular lymphoma: A comprehensive SEER analysis across consecutive treatment eras. <i>American Journal of Hematology</i> , 2014 , 89, 633-8	7.1	34
164	A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. <i>British Journal of Haematology</i> , 2014 , 165, 358-63	4.5	54
163	Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. <i>Annals of Oncology</i> , 2014 , 25, 2211-2217	10.3	90
162	The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models. <i>Clinical Cancer Research</i> , 2014 , 20, 6023-33	12.9	14
161	The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the modern era. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2778-84	1.9	23
160	Chemotherapeutic advancements in peripheral T-cell lymphoma. <i>Seminars in Hematology</i> , 2014 , 51, 17-24		11
159	Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients (Pts) with Epstein Barr Virus (EBV)+ and/or CD30+ Lymphoma: Phase I Results of an Ongoing Phase I-II Study. <i>Blood</i> , 2014 , 124, 3096-3096	2.2	8
158	Splenic Irradiation and a Reduced-Intensity Conditioning Regimen Prior to Allogeneic Stem-Cell Transplantation for Myelofibrosis. <i>Blood</i> , 2014 , 124, 3170-3170	2.2	3
157	The Lipid Addiction of Diffuse Large B-Cell Lymphoma (DLBCL) and Potential Treatment Strategies with Novel Fatty Acid Synthase (FASN) Small Molecule Inhibitors. <i>Blood</i> , 2014 , 124, 4490-4490	2.2	4
156	Hodgkin Lymphoma Type Post-Transplant Lymphoproliferative Disorder (HL-PTLD) after Solid Organ Transplant (SOT): A Comprehensive and Comparative Analysis of Disease Characteristics, Prognosis, and Survival. <i>Blood</i> , 2014 , 124, 502-502	2.2	1
155	Hodgkin lymphoma-like post-transplant lymphoproliferative disorder (HL-PTLD): Characteristics, survival, and prognostication in a large U.S. cohort.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8572-8572	2.2	

154	Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumor burden (HTB) indolent non-Hodgkin lymphoma (iNHL): A multicenter phase II study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8545-8545	2.2	
153	Peripheral T-cell lymphomas (PTCL) in the modern era: Prognosis and impact of therapy in a large U.S. multicenter cohort.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e19561-e19561	2.2	
152	Photopheresis As Part of Conditioning Reduces Incidence of Severe Graft Versus Host Disease: Fourteen Year Follow-up of a Novel Reduced Intensity Regimen for Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014 , 124, 5924-5924	2.2	
151	Strand-Specific Total RNA Sequencing Establishes the Complete Transcriptome and Alternative Splicing Repertoire in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2014 , 124, 864-864	2.2	1
150	The Bruton Tyrosine Kinase Inhibitor CC-292 in Diffuse Large B-Cell Lymphoma (DLBCL), T-Cell Lymphoma (TCL), and Hodgkin Lymphoma (HL): Induction of Cell Death and Examination of Rational Novel/Novel Therapeutic Combinations. <i>Blood</i> , 2014 , 124, 1772-1772	2.2	2
149	Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome. <i>Blood</i> , 2014 , 124, 1703-1703	2.2	
148	Genome-Wide Analysis Reveals MYC-Dependent Cell Death and Identifies Predictive Biomarkers of Ixazomib Sensitivity in Preclinical Models of T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL). <i>Blood</i> , 2014 , 124, 3120-3120	2.2	
147	Hepatitis B (HBV) Screening in Patients Receiving Rituximab: A Comprehensive Analysis Including Comparison of Adherence By Oncologists and Non-Oncologists. <i>Blood</i> , 2014 , 124, 2595-2595	2.2	
146	A Comparative Oncology Study of Canine and Human Genomics and Proteomics in Peripheral T-Cell Lymphoma (PTCL): Examination of Shared Oncogenic Signaling for Biomarker and Therapeutic Target Discovery. <i>Blood</i> , 2014 , 124, 3019-3019	2.2	
145	FDG-PET imaging for Hodgkin lymphoma: current use and future applications. <i>Clinical Advances in Hematology and Oncology</i> , 2014 , 12, 20-35	0.6	7
144	Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. <i>Current Hematologic Malignancy Reports</i> , 2013 , 8, 173-83	4.4	177
143	An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. <i>Annals of Oncology</i> , 2013 , 24, 257-63	10.3	249
142	Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML). <i>British Journal of Haematology</i> , 2013 , 160, 262-6	4.5	39
141	The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. <i>British Journal of Haematology</i> , 2013 , 161, 76-86	4.5	86
140	Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. <i>Cancer</i> , 2013 , 119, 3662-71	6.4	51
139	A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. <i>Annals of Oncology</i> , 2013 , 24, 3076-81	10.3	32
138	Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation. <i>Leukemia and Lymphoma</i> , 2013 , 54, 497-502	1.9	13
137	Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. <i>American Journal of Transplantation</i> , 2013 , 13, 1512-22	8.7	116

136	XII. Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes. <i>Hematological Oncology</i> , 2013 , 31 Suppl 1, 69-75	1.3	10
135	Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4132-9	2.2	63
134	Pre-diagnosis cigarette smoking and overall survival in non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2013 , 163, 352-6	4.5	7
133	A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. <i>British Journal of Haematology</i> , 2013 , 163, 55-61	4.5	36
132	Genetic heterogeneity of diffuse large B-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 1398-403	11.5	419
131	Targeting The Interactions Of Fatty Acid Metabolism With PI3K/mTOR and MAPK As a Novel Therapeutic Strategy In Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2013 , 122, 5133-5133	2.2	2
130	Impact Of Induction Regimen and Consolidative Stem Cell Transplantation In Patients With Double Hit Lymphoma (DHL): A Large Multicenter Retrospective Analysis. <i>Blood</i> , 2013 , 122, 640-640	2.2	6
129	Paradoxical regulation of hypoxia inducible factor-1[HIF-1] by histone deacetylase inhibitor in diffuse large B-cell lymphoma. <i>PLoS ONE</i> , 2013 , 8, e81333	3.7	16
128	Allogeneic and autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide conditioning therapy for relapsed/refractory non-Hodgkin lymphoma. <i>Modern Chemotherapy</i> , 2013 , 02, 57-65		
127	A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. <i>Blood</i> , 2012 , 119, 692-5	2.2	113
126	The genetic landscape of mutations in Burkitt lymphoma. <i>Nature Genetics</i> , 2012 , 44, 1321-5	36.3	422
125	Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis. <i>Annals of Oncology</i> , 2012 , 23, 2128-2137	10.3	66
124	Early posttransplant lymphoproliferative disease: clinicopathologic features and correlation with mTOR signaling pathway activation. <i>American Journal of Clinical Pathology</i> , 2012 , 138, 568-78	1.9	27
123	Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. <i>Cancer</i> , 2012 , 118, 3743-8	6.4	62
122	Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. <i>Current Treatment Options in Oncology</i> , 2012 , 13, 122-36	5.4	120
121	Analysis of very elderly (80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. <i>British Journal of Haematology</i> , 2012 , 156, 196-204	4.5	67
120	Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity. <i>Blood</i> , 2012 , 120, 1618-1618	2.2	2
119	A Phase 2 Clinical Trial Adding Rituximab to CODOX-M/IVAC for Untreated Burkitts Lymphoma: Correlative Analysis of Serum and CSF Rituximab Levels. <i>Blood</i> , 2012 , 120, 1640-1640	2.2	1

118	A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2012 , 120, 55-55	2.2	9
117	Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8060-8060	2.2	
116	The incorporation of rituximab (R) and liposomal doxorubicin (LD) into CODOX-m/IVAC for untreated Burkitt lymphoma (BL): Final results of a prospective multicenter phase II study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8080-8080	2.2	
115	The impact of race, age, and sex in follicular lymphoma (FL): A comprehensive SEER analysis in the pre- and post-rituximab (R) eras.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8072-8072	2.2	
114	Darinaparsin in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cells Lines and SCID Xenograft Mouse Models: Single-Agent Activity and Synergistic Cell Death Combined with a PI3K/mTOR Inhibitor. <i>Blood</i> , 2012 , 120, 1646-1646	2.2	
113	Fatty Acid Metabolism in Diffuse Large B-Cell Lymphoma (DLBCL): Interaction with Oncogenic Cell Signaling Pathways and the Identification of a Novel Treatment Paradigm.. <i>Blood</i> , 2012 , 120, 2711-2711	2.2	0
112	Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Blood Stem-Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Excellent Disease Control and Long-Term Survival Rates. <i>Blood</i> , 2012 , 120, 2024-2024	2.2	
111	The Impact of Race, Age, and Sex in Chronic Lymphocytic Leukemia (CLL): A Comprehensive SEER Analysis in the Pre and Post Rituximab (R) Eras.. <i>Blood</i> , 2012 , 120, 2877-2877	2.2	
110	Hepatitis B Virus (HBV) Screening in Hematology/Oncology Patients Who Receive Rituximab: Continued Need for Evidence-Based Standardized Recommendations and Effective Implementation Into Clinical Practice. <i>Blood</i> , 2012 , 120, 970-970	2.2	
109	A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE®) Therapy for Untreated High Tumor Burden Indolent Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2012 , 120, 1642-1642	2.2	
108	Diffuse Large B-Cell Lymphomas Utilize Endogenous and Exogenous Fatty Acids for Cell Growth and Survival. <i>Blood</i> , 2012 , 120, 1581-1581	2.2	
107	The 2nd Generation Proteasome Inhibitor, MLN2238: Potent Induction of Cell Death in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cell Lines and in Two Human Lymphoma Xenograft Models.. <i>Blood</i> , 2012 , 120, 2767-2767	2.2	
106	The Impact of Race, Age, and Sex in Follicular Lymphoma (FL): A Comprehensive SEER Analysis in the Pre- and Post-Rituximab Eras. <i>Blood</i> , 2012 , 120, 1576-1576	2.2	
105	Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort.. <i>Blood</i> , 2012 , 120, 2728-2728	2.2	
104	Influence of Lifestyle Factors On Expression of Tumor-Related Microenvironment T-Cells and Impact On Survival of Follicular Lymphoma (FL).. <i>Blood</i> , 2012 , 120, 2694-2694	2.2	
103	The Impact of Cigarette Smoking On Overall Survival in Non-Hodgkin Lymphoma. <i>Blood</i> , 2012 , 120, 5100-5100	2.2	
102	ID3 Is a Novel Tumor Suppressor Gene in Burkitt Lymphom. <i>Blood</i> , 2012 , 120, 898-898	2.2	
101	The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. <i>Blood</i> , 2011 , 118, 1052-61	2.2	28

100	Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. <i>Annals of Oncology</i> , 2011 , 22, 1170-1180	10.3	237
99	Dietary intake of fruit and vegetables and risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2011 , 22, 1183-95	2.8	20
98	Clinical, morphologic, immunophenotypic, and molecular cytogenetic assessment of CD4-/CD8- T-cell large granular lymphocytic leukemia. <i>American Journal of Clinical Pathology</i> , 2011 , 136, 289-99	1.9	36
97	A Phase I/II Trial of Combination Gemcitabine and Bortezomib (VELCADE [®]) for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NHL) and Aggressive B-Cell NHL. <i>Blood</i> , 2011 , 118, 1646-1646	2.2	1
96	Multicenter Analysis of Elderly Hodgkin Lymphoma (eHL): Outcomes and Prognostic Factors in the Modern Era. <i>Blood</i> , 2011 , 118, 2625-2625	2.2	1
95	Primary Central Nervous System (PCNS) Post-Transplant Lymphoproliferative Disease (PTLD): An International Report of 65 Cases in the Modern Era. <i>Blood</i> , 2011 , 118, 879-879	2.2	2
94	Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. <i>Blood</i> , 2011 , 118, 94-94	2.2	3
93	Burkitt Lymphoma and Leukemia 2011 , 175-210		
92	Whole Genome and Exome Sequencing Reveals the Genetic Landscape of Burkitt Lymphoma. <i>Blood</i> , 2011 , 118, 433-433	2.2	
91	Multicenter Analysis of Very Elderly Indolent and Aggressive Non-Hodgkin Lymphoma (NHL): Impact of Functional Status on Outcome. <i>Blood</i> , 2011 , 118, 3668-3668	2.2	
90	Integration of Rituximab and Liposomal Doxorubicin (DOXIL [®]) Into CODOX-M/IVAC for HIV-Negative and HIV+ Adults with Untreated Burkitt's Lymphoma (BL): Results of a Prospective Multicenter Phase II Study. <i>Blood</i> , 2011 , 118, 2669-2669	2.2	
89	Busulfan, Cyclophosphamide, and Etoposide (Bu/Cy/VP-16) Is An Effective Conditioning Regimen Prior to Allogeneic or Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Non-Hodgkin's Lymphoma. <i>Blood</i> , 2011 , 118, 4499-4499	2.2	
88	Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project. <i>Blood</i> , 2011 , 118, 4112-4112	2.2	1
87	Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms. <i>British Journal of Haematology</i> , 2010 , 150, 365-9	4.5	16
86	All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2010 , 150, 158-69	4.5	34
85	Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1038-46	2.2	243
84	Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. <i>Clinical Cancer Research</i> , 2010 , 16, 719-26	12.9	40
83	Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of <i>Andrographis paniculata</i> . <i>Clinical Cancer Research</i> , 2010 , 16, 4755-68	12.9	68

82	Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1017-24	2.2	47
81	Reply to D. Dierickx et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e367-e368	2.2	1
80	Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1163-77	1.9	10
79	Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. <i>Blood</i> , 2010 , 116, e118-27	2.2	167
78	Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. <i>Current Oncology Reports</i> , 2010 , 12, 383-94	6.3	108
77	Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcR11a 158(V/F) polymorphism. <i>American Journal of Hematology</i> , 2010 , 85, 810-2	7.1	43
76	Results of a Prospective Multicenter Phase II Study of Initial Treatment with Methotrexate In LGL Leukemia (ECOG Protocol E5998). <i>Blood</i> , 2010 , 116, 702-702	2.2	2
75	Alternative Splicing Is a Major Mechanism of Gene Regulation In Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2010 , 116, 803-803	2.2	
74	Multicenter Analysis of 150 Very Elderly Non-Hodgkin's Lymphoma (NHL) Patients: Impact of Comorbidities and Response to Initial Therapy on Survival. <i>Blood</i> , 2010 , 116, 3124-3124	2.2	
73	Improving outcomes in PTLD. <i>Oncology</i> , 2010 , 24, 944, 946-7	1.8	
72	Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1653-9	2.2	94
71	PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. <i>Clinical Cancer Research</i> , 2009 , 15, 3354-65	12.9	80
70	The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial. <i>Clinical Cancer Research</i> , 2009 , 15, 6462-71	12.9	12
69	Vaccination history and risk of non-Hodgkin lymphoma: a population-based, case-control study. <i>Cancer Causes and Control</i> , 2009 , 20, 517-23	2.8	15
68	Primary mediastinal large B-cell lymphoma in HIV: report of two cases. <i>Journal of Hematopathology</i> , 2009 , 2, 45-9	0.4	3
67	Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1434-41	1.9	26
66	Curing Hodgkin's lymphoma: quantity and quality. <i>Lancet Oncology, The</i> , 2009 , 10, 1134-5	21.7	3
65	Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. <i>Blood</i> , 2009 , 113, 4834-40	2.2	718

64	Glutathione Depletion Enhances Arsenic Trioxide-Induced Apoptosis in Lymphoma Cells through Mitochondrial and Caspase-Independent Mechanisms.. <i>Blood</i> , 2009 , 114, 2708-2708	2.2	1
63	Mitochondrial-Mediated Apoptosis in Lymphoma by the Diterpenoid Lactone Andrographolide (Andro), the Active Component of <i>Andrographis paniculata</i> .. <i>Blood</i> , 2009 , 114, 2710-2710	2.2	1
62	Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma.. <i>Blood</i> , 2009 , 114, 2726-2726	2.2	4
61	The Novel 2nd Generation Small Molecule MEK Inhibitor, AZD-6244, Induces Cell Death in Lymphoma Cells Lines, Primary Cells, and in a Human Lymphoma Xenograft Model.. <i>Blood</i> , 2009 , 114, 285-285	2.2	2
60	All Trans Retinoic Acid Nanodisks Enhance Retinoic Acid Receptor-Mediated Apoptosis and Cell Cycle Arrest in Mantle Cell Lymphoma.. <i>Blood</i> , 2009 , 114, 3722-3722	2.2	
59	PX-478, a Novel Small Molecule Inhibitor of Hypoxia Inducible Factor-1 (HIF-1) Downregulates HIF and Induces Cytotoxicity in Diffuse Large B Cell Lymphoma Cells.. <i>Blood</i> , 2009 , 114, 2713-2713	2.2	1
58	A Comprehensive Identification of the MicroRNA Transcriptome and Its Application in B Cell Malignancies.. <i>Blood</i> , 2009 , 114, 2403-2403	2.2	
57	A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. <i>British Journal of Haematology</i> , 2008 , 140, 385-93	4.5	42
56	Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family. <i>British Journal of Haematology</i> , 2008 , 141, 676-80	4.5	35
55	Treatment of Hodgkin lymphoma: the past, present, and future. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 543-56		75
54	The challenges of epidemiologic research in non-Hodgkin lymphoma. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 300, 2059-61	27.4	13
53	CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease. <i>American Journal of Clinical Pathology</i> , 2008 , 130, 166-77	1.9	44
52	Dietary factors and risk of t(14;18)-defined subgroups of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2008 , 19, 859-67	2.8	22
51	Hodgkin lymphoma in older patients: an uncommon disease in need of study. <i>Oncology</i> , 2008 , 22, 1369-78		31
50	Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2007 , 7, 472-4		9
49	Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. <i>Cancer</i> , 2007 , 109, 1532-5	6.4	177
48	Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. <i>Leukemia Research</i> , 2007 , 31, 599-604	2.7	136
47	Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. <i>Bone Marrow Transplantation</i> , 2007 , 39, 425-9	4.4	173

46	Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. <i>Bone Marrow Transplantation</i> , 2007 , 40, 185-92	4.4	125
45	Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. <i>Bone Marrow Transplantation</i> , 2007 , 40, 451-6	4.4	185
44	G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. <i>British Journal of Haematology</i> , 2007 , 137, 545-52	4.5	61
43	Obesity and risk of non-Hodgkin lymphoma (United States). <i>Cancer Causes and Control</i> , 2007 , 18, 677-85	2.8	34
42	Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options. <i>Current Treatment Options in Oncology</i> , 2007 , 8, 352-74	5.4	13
41	Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. <i>Archives of Internal Medicine</i> , 2007 , 167, 1041-9		37
40	Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia. <i>American Journal of Clinical Pathology</i> , 2007 , 127, 182-91	1.9	26
39	Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2007 , 18, 679-88	10.3	22
38	Sun exposure and non-Hodgkin lymphoma: a population-based, case-control study. <i>European Journal of Cancer</i> , 2007 , 43, 2388-95	7.5	26
37	Comparative Analysis of Flow Cytometric Techniques in Assessment of ZAP-70 Expression in Relation to IgV H Mutational Status in Chronic Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2007 , 127, 182-191	1.9	
36	Hypoxia-Inducible Factor-Alpha (HIF-1) Activation in Non-Hodgkin Lymphoma (NHL): Relationship to the Thioredoxin Family and Correlation with Survival by Tissue Microarray (TMA).. <i>Blood</i> , 2007 , 110, 3587-3587	2.2	
35	Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 296, 2558-60	27.4	107
34	Oxidative stress and apoptosis: a new treatment paradigm in cancer. <i>Frontiers in Bioscience - Landmark</i> , 2006 , 11, 300-12	2.8	166
33	T-cell non-Hodgkin lymphoma. <i>Blood</i> , 2006 , 107, 1255-64	2.2	178
32	Targeting angiogenesis for the treatment of sarcoma. <i>Current Opinion in Oncology</i> , 2006 , 18, 354-9	4.2	35
31	Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. <i>British Journal of Haematology</i> , 2006 , 135, 642-50	4.5	112
30	Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. <i>Bone Marrow Transplantation</i> , 2006 , 37, 997-1001	4.4	71
29	Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?. <i>Bone Marrow Transplantation</i> , 2006 , 38, 95-100	4.4	41

28	T-Cell Non-Hodgkin's Lymphoma 2006 , 161-220		0
27	Comparison of Out-of-Pocket Costs and Quality of Life (QOL) for Patients (pts) with Hodgkin's Disease (HD), Indolent Non-Hodgkin's Lymphoma (INHL) and Aggressive Non-Hodgkin's Lymphoma (ANHL).. <i>Blood</i> , 2006 , 108, 3332-3332	2.2	
26	Clinical characteristics of erythropoietin-associated pure red cell aplasia. <i>Best Practice and Research in Clinical Haematology</i> , 2005 , 18, 467-72	4.2	16
25	Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. <i>Best Practice and Research in Clinical Haematology</i> , 2005 , 18, 481-9	4.2	12
24	Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. <i>Blood</i> , 2005 , 105, 1265-73	2.2	61
23	Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. <i>Blood</i> , 2005 , 106, 3343-7	2.2	83
22	Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?. <i>Bone Marrow Transplantation</i> , 2005 , 35, 243-6	4.4	28
21	Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies. <i>Current Treatment Options in Oncology</i> , 2005 , 6, 289-96	5.4	12
20	The Research on Adverse Drug Events and Reports (RADAR) project. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 293, 2131-40	27.4	86
19	Dramatic and Sustained Hematologic Complete Remission with Denileukin Diftitox (ONTAK [®]) in a Patient with Refractory Adult T-Cell Leukemia (ATL).. <i>Blood</i> , 2005 , 106, 4638-4638	2.2	
18	Combination of Motexafin Gadolinium (MGd) with 90Y Ibritumomab Tiuxetan (Zevalin [®] ; 90Yttrium-Zevalin) Radioimmunotherapy (RIT) Produces High Complete Remission Rates in Relapsed Rituximab-Refractory Follicular Non- Hodgkin's Lymphoma (NHL).. <i>Blood</i> , 2005 , 106, 2450-2450	2.2	
17	Thalidomide-Associated Thromboembolism in Cancer: Reimbursement for Thalidomide [®] Off-Label Prescribing under the 2004 Medicare Oral Pharmaceutical Demonstration Project Raises Concerns.. <i>Blood</i> , 2005 , 106, 2244-2244	2.2	
16	Allogeneic Stem Cell Transplantation (AlloSCT) for Relapsed Hodgkin's Lymphoma (HL) Following Autologous Stem Cell Transplantation (AuSCT): Improved Progression-Free Survival (PFS) in Patients with Graft vs Host-Disease (GvHD) Suggests a Graft vs Lymphoma (GVL) Effect.. <i>Blood</i> , 2005 , 106, 5455-5455	2.2	
15	Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent. <i>Clinical Cancer Research</i> , 2004 , 10, 1481-91	12.9	41
14	Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. <i>Bone Marrow Transplantation</i> , 2004 , 34, 561-71	4.4	83
13	Treatment of T-cell non-Hodgkin's lymphoma. <i>Current Treatment Options in Oncology</i> , 2004 , 5, 289-303	5.4	32
12	The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. <i>Leukemia Research</i> , 2004 , 28, 891-900	2.7	148
11	Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond. <i>Clinical Lymphoma and Myeloma</i> , 2004 , 5 Suppl 1, S11-5		4

10	Pure red-cell aplasia and epoetin therapy. <i>New England Journal of Medicine</i> , 2004 , 351, 1403-8	59.2	338
9	Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer. <i>Current Opinion in Oncology</i> , 2004 , 16, 576-80	4.2	46
8	Long-Term Follow-Up of Recombinant Human Erythropoietin (epoetin)Induced Pure Red Cell Aplasia (PRCA): A Comparison of Data Collected through Active and Passive Pharmacovigilance Efforts.. <i>Blood</i> , 2004 , 104, 5319-5319	2.2	1
7	Molecular etiology of mature T-cell non-Hodgkin's lymphomas. <i>Frontiers in Bioscience - Landmark</i> , 2003 , 8, d156-75	2.8	13
6	Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies. <i>Blood</i> , 2003 , 102, 297-302	2.2	37
5	Burkitt's and Burkitt-like lymphoma. <i>Current Treatment Options in Oncology</i> , 2002 , 3, 291-305	5.4	16
4	TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology. <i>Transplantation</i> , 2002 , 74, 885-7	1.8	24
3	T-cell lymphoma 2001 , 215-232		
2	T-cell non-Hodgkin lymphoma226-253		
1	Hodgkin lymphoma: epidemiology, diagnosis, and treatment367-403		